Benzinga | Oct 26, 2020 08:01AM EDT

Piper Sandler Maintains Overweight on Mirati Therapeutics, Raises Price Target to $210

Piper Sandler analyst Tyler Van Buren maintains Mirati Therapeutics (NASDAQ:MRTX) with a Overweight and raises the price target from $170 to $210.